Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Embolization, Therapeutic | 14 | 2023 | 551 | 2.860 |
Why?
|
| Hematoma, Subdural, Chronic | 6 | 2023 | 9 | 2.420 |
Why?
|
| Bone Screws | 8 | 2015 | 84 | 2.300 |
Why?
|
| Atlanto-Axial Joint | 8 | 2015 | 25 | 2.000 |
Why?
|
| Tinnitus | 2 | 2023 | 38 | 1.750 |
Why?
|
| Intracranial Aneurysm | 8 | 2022 | 123 | 1.550 |
Why?
|
| Meningeal Arteries | 6 | 2023 | 9 | 1.320 |
Why?
|
| Stroke | 13 | 2023 | 1144 | 1.320 |
Why?
|
| Cranial Sinuses | 2 | 2023 | 24 | 1.110 |
Why?
|
| Neurosurgical Procedures | 6 | 2020 | 609 | 1.050 |
Why?
|
| Endovascular Procedures | 7 | 2022 | 516 | 1.000 |
Why?
|
| Stents | 10 | 2023 | 1096 | 0.940 |
Why?
|
| Cervical Vertebrae | 2 | 2015 | 205 | 0.940 |
Why?
|
| Cerebral Revascularization | 3 | 2023 | 23 | 0.890 |
Why?
|
| Constriction, Pathologic | 7 | 2023 | 310 | 0.860 |
Why?
|
| Drainage | 2 | 2016 | 416 | 0.850 |
Why?
|
| Thrombectomy | 8 | 2023 | 158 | 0.750 |
Why?
|
| Spinal Fusion | 7 | 2018 | 149 | 0.740 |
Why?
|
| Brain Ischemia | 5 | 2023 | 292 | 0.730 |
Why?
|
| Cervical Atlas | 2 | 2016 | 19 | 0.680 |
Why?
|
| Cerebral Hemorrhage | 4 | 2023 | 183 | 0.650 |
Why?
|
| Joint Instability | 3 | 2013 | 88 | 0.640 |
Why?
|
| Vertebral Artery | 3 | 2014 | 42 | 0.640 |
Why?
|
| Craniotomy | 3 | 2016 | 304 | 0.620 |
Why?
|
| Arthrodesis | 2 | 2015 | 12 | 0.570 |
Why?
|
| Hematoma, Subdural | 1 | 2016 | 28 | 0.560 |
Why?
|
| Angioplasty | 3 | 2022 | 94 | 0.560 |
Why?
|
| Neurosurgery | 2 | 2014 | 108 | 0.550 |
Why?
|
| Treatment Outcome | 34 | 2023 | 32848 | 0.540 |
Why?
|
| Tranexamic Acid | 1 | 2016 | 47 | 0.530 |
Why?
|
| Antifibrinolytic Agents | 1 | 2016 | 68 | 0.520 |
Why?
|
| Orthopedic Procedures | 1 | 2015 | 146 | 0.470 |
Why?
|
| Anticoagulants | 3 | 2023 | 787 | 0.470 |
Why?
|
| Spinal Injuries | 1 | 2013 | 32 | 0.460 |
Why?
|
| Arachnoid | 2 | 2023 | 13 | 0.460 |
Why?
|
| Aneurysm, Ruptured | 2 | 2015 | 45 | 0.460 |
Why?
|
| Carotid Artery Diseases | 1 | 2014 | 196 | 0.440 |
Why?
|
| Prostheses and Implants | 1 | 2014 | 295 | 0.410 |
Why?
|
| Heparin | 1 | 2013 | 360 | 0.390 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 260 | 0.390 |
Why?
|
| Arteries | 1 | 2012 | 274 | 0.380 |
Why?
|
| Aneurysm, False | 1 | 2012 | 153 | 0.380 |
Why?
|
| Betacoronavirus | 3 | 2020 | 527 | 0.380 |
Why?
|
| Middle Cerebral Artery | 3 | 2021 | 85 | 0.370 |
Why?
|
| Spinal Cord | 2 | 2021 | 690 | 0.370 |
Why?
|
| Vascular Diseases | 1 | 2012 | 246 | 0.360 |
Why?
|
| Humans | 65 | 2023 | 261506 | 0.350 |
Why?
|
| Venous Thromboembolism | 1 | 2013 | 335 | 0.330 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 1085 | 0.320 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 651 | 0.310 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 715 | 0.310 |
Why?
|
| Retrospective Studies | 24 | 2023 | 37905 | 0.310 |
Why?
|
| Surgeons | 1 | 2015 | 519 | 0.310 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2022 | 95 | 0.310 |
Why?
|
| Middle Aged | 29 | 2023 | 86204 | 0.300 |
Why?
|
| Blood Vessel Prosthesis | 3 | 2020 | 412 | 0.290 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 860 | 0.280 |
Why?
|
| Aged | 23 | 2023 | 70117 | 0.280 |
Why?
|
| Angiography | 2 | 2020 | 360 | 0.270 |
Why?
|
| Male | 31 | 2023 | 123000 | 0.250 |
Why?
|
| Reperfusion | 2 | 2020 | 24 | 0.240 |
Why?
|
| Female | 32 | 2023 | 141928 | 0.240 |
Why?
|
| Moyamoya Disease | 1 | 2023 | 42 | 0.220 |
Why?
|
| Vasospasm, Intracranial | 1 | 2022 | 22 | 0.220 |
Why?
|
| Skull | 3 | 2023 | 231 | 0.220 |
Why?
|
| Balloon Embolectomy | 2 | 2018 | 2 | 0.220 |
Why?
|
| Fetal Stem Cells | 2 | 2012 | 4 | 0.220 |
Why?
|
| Adult | 18 | 2023 | 77950 | 0.210 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2021 | 18 | 0.200 |
Why?
|
| Urinary Retention | 1 | 2021 | 21 | 0.200 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2012 | 90 | 0.200 |
Why?
|
| Drug-Eluting Stents | 1 | 2023 | 131 | 0.200 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2021 | 20 | 0.200 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 55 | 0.200 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 29902 | 0.200 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 160 | 0.200 |
Why?
|
| Temporal Arteries | 1 | 2021 | 40 | 0.190 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2012 | 99 | 0.190 |
Why?
|
| New York City | 4 | 2021 | 74 | 0.190 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2020 | 19 | 0.190 |
Why?
|
| Brain Infarction | 1 | 2020 | 31 | 0.190 |
Why?
|
| Pons | 1 | 2020 | 51 | 0.190 |
Why?
|
| Radiology, Interventional | 1 | 2021 | 138 | 0.190 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 42 | 0.180 |
Why?
|
| Empirical Research | 1 | 2019 | 11 | 0.180 |
Why?
|
| Carotid Stenosis | 1 | 2021 | 176 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 58 | 0.180 |
Why?
|
| Comprehensive Health Care | 1 | 2020 | 49 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2020 | 7551 | 0.180 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 70 | 0.180 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 324 | 0.170 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 90 | 0.170 |
Why?
|
| Arteriovenous Fistula | 1 | 2020 | 92 | 0.170 |
Why?
|
| Pandemics | 4 | 2021 | 1559 | 0.170 |
Why?
|
| Skull Base | 2 | 2020 | 199 | 0.170 |
Why?
|
| Carotid Artery, Internal | 2 | 2021 | 77 | 0.170 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 142 | 0.170 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2020 | 164 | 0.160 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 257 | 0.160 |
Why?
|
| Biomechanical Phenomena | 2 | 2018 | 338 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2020 | 333 | 0.160 |
Why?
|
| Spinal Diseases | 1 | 2018 | 125 | 0.150 |
Why?
|
| Lumbar Vertebrae | 1 | 2018 | 245 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 348 | 0.140 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 421 | 0.140 |
Why?
|
| Neuroendoscopy | 1 | 2016 | 31 | 0.140 |
Why?
|
| Nervous System Neoplasms | 1 | 2016 | 36 | 0.140 |
Why?
|
| Epidermal Cyst | 1 | 2016 | 46 | 0.140 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2016 | 41 | 0.140 |
Why?
|
| Dermoid Cyst | 1 | 2016 | 38 | 0.140 |
Why?
|
| Finite Element Analysis | 1 | 2016 | 57 | 0.140 |
Why?
|
| Radiosurgery | 2 | 2016 | 1330 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2020 | 1244 | 0.140 |
Why?
|
| Epilepsy | 2 | 2016 | 883 | 0.130 |
Why?
|
| Confidence Intervals | 2 | 2014 | 756 | 0.130 |
Why?
|
| Carotid-Cavernous Sinus Fistula | 1 | 2015 | 9 | 0.130 |
Why?
|
| Models, Anatomic | 1 | 2016 | 154 | 0.130 |
Why?
|
| Vascular Access Devices | 1 | 2015 | 51 | 0.130 |
Why?
|
| Tuberous Sclerosis | 1 | 2016 | 136 | 0.120 |
Why?
|
| Health Personnel | 1 | 2020 | 625 | 0.120 |
Why?
|
| Printing, Three-Dimensional | 1 | 2016 | 129 | 0.120 |
Why?
|
| Vascular Patency | 1 | 2015 | 218 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2016 | 217 | 0.120 |
Why?
|
| Computer-Assisted Instruction | 1 | 2014 | 81 | 0.110 |
Why?
|
| Osteoarthritis, Spine | 1 | 2012 | 2 | 0.110 |
Why?
|
| Quality Improvement | 1 | 2020 | 851 | 0.110 |
Why?
|
| Cadaver | 1 | 2013 | 237 | 0.110 |
Why?
|
| Braces | 1 | 2012 | 12 | 0.110 |
Why?
|
| Alberta | 2 | 2023 | 65 | 0.110 |
Why?
|
| Physician's Role | 1 | 2015 | 238 | 0.110 |
Why?
|
| Patients | 1 | 2015 | 245 | 0.110 |
Why?
|
| Arachnoid Cysts | 1 | 2012 | 12 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2013 | 495 | 0.110 |
Why?
|
| Data Collection | 1 | 2015 | 620 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 4849 | 0.100 |
Why?
|
| Thrombosis | 1 | 2018 | 781 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2022 | 6100 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 698 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2022 | 1797 | 0.100 |
Why?
|
| Thoracic Vertebrae | 1 | 2012 | 186 | 0.100 |
Why?
|
| Hypothalamic Diseases | 1 | 2012 | 66 | 0.100 |
Why?
|
| Glioma | 1 | 2022 | 1963 | 0.100 |
Why?
|
| Hospitalization | 2 | 2020 | 2083 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2013 | 414 | 0.100 |
Why?
|
| Wounds and Injuries | 1 | 2015 | 399 | 0.100 |
Why?
|
| Hamartoma | 1 | 2012 | 115 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 573 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 1011 | 0.090 |
Why?
|
| Vagus Nerve Stimulation | 1 | 2011 | 59 | 0.090 |
Why?
|
| Radiography | 1 | 2014 | 1904 | 0.090 |
Why?
|
| Young Adult | 5 | 2016 | 21445 | 0.090 |
Why?
|
| Abnormalities, Multiple | 1 | 2016 | 998 | 0.090 |
Why?
|
| Time Factors | 4 | 2020 | 12926 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 3719 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2016 | 2803 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 925 | 0.090 |
Why?
|
| Risk | 1 | 2013 | 1972 | 0.080 |
Why?
|
| Myocardial Ischemia | 1 | 2012 | 435 | 0.080 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 918 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2014 | 671 | 0.080 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 292 | 0.080 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 4320 | 0.080 |
Why?
|
| Neoplasms | 1 | 2014 | 15193 | 0.080 |
Why?
|
| Preoperative Care | 1 | 2014 | 1529 | 0.080 |
Why?
|
| Pain | 1 | 2015 | 1658 | 0.070 |
Why?
|
| Cerebral Angiography | 2 | 2018 | 129 | 0.070 |
Why?
|
| Adolescent | 4 | 2016 | 31252 | 0.070 |
Why?
|
| Prevalence | 1 | 2013 | 3260 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 1360 | 0.060 |
Why?
|
| Myocardium | 1 | 2011 | 1313 | 0.060 |
Why?
|
| Child | 6 | 2016 | 29154 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8865 | 0.060 |
Why?
|
| Cell Movement | 1 | 2011 | 2466 | 0.060 |
Why?
|
| Polymethyl Methacrylate | 1 | 2023 | 41 | 0.060 |
Why?
|
| Cerebral Infarction | 1 | 2023 | 59 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2014 | 1375 | 0.060 |
Why?
|
| Anterior Cerebral Artery | 1 | 2022 | 10 | 0.060 |
Why?
|
| Intention to Treat Analysis | 1 | 2022 | 130 | 0.050 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 1374 | 0.050 |
Why?
|
| Dilatation | 1 | 2022 | 83 | 0.050 |
Why?
|
| Walruses | 1 | 2021 | 1 | 0.050 |
Why?
|
| Paraparesis | 1 | 2021 | 17 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2022 | 121 | 0.050 |
Why?
|
| Carotid Artery, Common | 1 | 2021 | 91 | 0.050 |
Why?
|
| United States | 2 | 2020 | 15433 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2022 | 219 | 0.050 |
Why?
|
| Retreatment | 1 | 2022 | 452 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2022 | 239 | 0.050 |
Why?
|
| Catheters | 1 | 2021 | 126 | 0.050 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2020 | 49 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2011 | 4078 | 0.050 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2020 | 10 | 0.050 |
Why?
|
| Constipation | 1 | 2021 | 177 | 0.050 |
Why?
|
| Blood Sedimentation | 1 | 2020 | 35 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 68 | 0.050 |
Why?
|
| Troponin | 1 | 2020 | 92 | 0.050 |
Why?
|
| Causality | 1 | 2020 | 178 | 0.050 |
Why?
|
| Prone Position | 1 | 2020 | 56 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2020 | 56 | 0.040 |
Why?
|
| Green Fluorescent Proteins | 2 | 2012 | 694 | 0.040 |
Why?
|
| Propensity Score | 1 | 2023 | 750 | 0.040 |
Why?
|
| Radial Artery | 1 | 2020 | 50 | 0.040 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 64 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2020 | 149 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 7222 | 0.040 |
Why?
|
| Workflow | 1 | 2020 | 275 | 0.040 |
Why?
|
| Aphasia | 1 | 2018 | 21 | 0.040 |
Why?
|
| Operating Rooms | 1 | 2020 | 122 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 5047 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 220 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 475 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2014 | 5542 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2020 | 264 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 195 | 0.040 |
Why?
|
| Range of Motion, Articular | 1 | 2018 | 144 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2023 | 12873 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 479 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2020 | 403 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2023 | 1863 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2292 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 795 | 0.030 |
Why?
|
| Brain | 2 | 2022 | 4113 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 7702 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2018 | 703 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2015 | 118 | 0.030 |
Why?
|
| Cerebral Arteries | 1 | 2015 | 73 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 297 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 2352 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 17523 | 0.030 |
Why?
|
| Zygapophyseal Joint | 1 | 2012 | 15 | 0.030 |
Why?
|
| Neck Pain | 1 | 2012 | 39 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 4758 | 0.030 |
Why?
|
| CDX2 Transcription Factor | 1 | 2011 | 37 | 0.030 |
Why?
|
| Animals | 4 | 2021 | 59536 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 14889 | 0.020 |
Why?
|
| Headache | 1 | 2012 | 163 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 521 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 6682 | 0.020 |
Why?
|
| Infant | 2 | 2016 | 13310 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 482 | 0.020 |
Why?
|
| Incidence | 1 | 2020 | 5673 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 1062 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2011 | 330 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2016 | 16273 | 0.020 |
Why?
|
| Vision Disorders | 1 | 2012 | 245 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 4744 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 664 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2011 | 1618 | 0.020 |
Why?
|
| Pregnancy | 2 | 2012 | 7573 | 0.020 |
Why?
|
| Calcinosis | 1 | 2012 | 423 | 0.020 |
Why?
|
| Reoperation | 1 | 2012 | 1382 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2011 | 431 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2011 | 891 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12221 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2011 | 898 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2011 | 1143 | 0.020 |
Why?
|
| Myocytes, Cardiac | 1 | 2011 | 764 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 3033 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2011 | 1945 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 3443 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 4143 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 8223 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 5637 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2012 | 6942 | 0.010 |
Why?
|
| Mice | 2 | 2012 | 34495 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2011 | 5270 | 0.010 |
Why?
|